Immunomet Therapeutics Inc.’s chief scientific officer, Sanghee Yoo, told BioWorld Today that $5.2 million in series A money will take the company to the start of phase I trials with oxidative phosphorylation (OXPHOS) inhibitor IM156 and fund operations into 2017, though the firm has “not provided specific details” on an immuno-oncology program, also in the pipeline, he said.